Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram.
BACKGROUND This study examined the potential of an antidepressant drug , escitalopram , to improve depression , resilience to stress , and quality of life in family dementia caregivers in a r and omized placebo-controlled double-blinded trial . METHODS Forty family caregivers ( 43 - 91 years of age , 25 children and 15 spouses ; 26 women ) who were taking care of their relatives with Alzheimer disease were r and omized to receive either escitalopram 10 mg/day or placebo for 12 weeks . Severity of depression , resilience , burden , distress , quality of life , and severity of care-recipient 's cognitive and behavioral disturbances were assessed at baseline and over the course of the study . The Hamilton Depression Rating Scale scores at baseline ranged between 10 and 28 . The groups were stratified by the diagnosis of major and minor depression . RESULTS Most outcomes favored escitalopram over placebo . The severity of depression improved , and the remission rate was greater with the drug compared with placebo . Measures of anxiety , resilience , burden , and distress improved on escitalopram compared with placebo . DISCUSSION Among caregivers , this small r and omized controlled trial found that escitalopram use result ed in improvement in depression , resilience , burden and distress , and quality of life . Our results need to be confirmed in a larger sample
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .